Overview

All Sanguine study protocols and their resulting samples, which include all Sanguine at-home and apheresis collection programs, are conducted under an Institutional Review Board (IRB). Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant.

Sanguine’s LeukoCore™ RUO leukopaks provide a high concentration of immune cells from a single donor as the white blood cells are extracted from the peripheral blood. Billions of cells from a single donor offer a reliable and consistent source of high-quality immune cells for drug development, cell therapy, and immunology research. Available fresh or cryopreserved in full- and half-packs, our leukopaks are collected directly from our extensive Donor Network, allowing us to recruit, screen, and recall donors to meet complex inclusion and exclusion (I/E) criteria. Sanguine’s LeukoCore™ RUO leukopaks are collected on the Spectra Optia® Apheresis System. Our leukopaks include donor demographics, verified conditions via donor electronic medical records, and infectious disease testing. Donors are recallable, and screening donors before purchasing a half- or full-pack is an option with LeukoLots™. HLA typing is available for an additional fee.

Well-characterized leukopaks for melanoma research supports studies on skin cancer progression, immune evasion, and therapeutic development for improved treatment and early detection strategies.